Literature DB >> 12686600

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Pipsa Saharinen1, Mauno Vihinen, Olli Silvennoinen.   

Abstract

Jak tyrosine kinases have a unique domain structure containing a kinase domain (JH1) adjacent to a catalytically inactive pseudokinase domain (JH2). JH2 is crucial for inhibition of basal Jak activity, but the mechanism of this regulation has remained elusive. We show that JH2 negatively regulated Jak2 in bacterial cells, indicating that regulation is an intrinsic property of Jak2. JH2 suppressed basal Jak2 activity by lowering the V(max) of Jak2, whereas JH2 did not affect the K(m) of Jak2 for a peptide substrate. Three inhibitory regions (IR1-3) within JH2 were identified. IR3 (residues 758-807), at the C terminus of JH2, directly inhibited JH1, suggesting an inhibitory interaction between IR3 and JH1. Molecular modeling of JH2 showed that IR3 could form a stable alpha-helical fold, supporting that IR3 could independently inhibit JH1. IR2 (725-757) in the C-terminal lobe of JH2, and IR1 (619-670), extending from the N-terminal to the C-terminal lobe, enhanced IR3-mediated inhibition of JH1. Disruption of IR3 either by mutations or a small deletion increased basal Jak2 activity, but abolished interferon-gamma-inducible signaling. Together, the results provide evidence for autoinhibition of a Jak family kinase and identify JH2 regions important for autoregulation of Jak2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12686600      PMCID: PMC153113          DOI: 10.1091/mbc.e02-06-0342

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  50 in total

1.  TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B.

Authors:  M P Myers; J N Andersen; A Cheng; M L Tremblay; C M Horvath; J P Parisien; A Salmeen; D Barford; N K Tonks
Journal:  J Biol Chem       Date:  2001-11-01       Impact factor: 5.157

2.  MULTICOMP: a program package for multiple sequence comparison.

Authors:  M Vihinen; A Euranto; P Luostarinen; O Nevalainen
Journal:  Comput Appl Biosci       Date:  1992-02

3.  SH2-B family members differentially regulate JAK family tyrosine kinases.

Authors:  Karen B O'Brien; John J O'Shea; Christin Carter-Su
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

4.  Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways.

Authors:  H Luo; P Rose; D Barber; W P Hanratty; S Lee; T M Roberts; A D D'Andrea; C R Dearolf
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

5.  Using CLUSTAL for multiple sequence alignments.

Authors:  D G Higgins; J D Thompson; T J Gibson
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

6.  Crystal structure of the Src family tyrosine kinase Hck.

Authors:  F Sicheri; I Moarefi; J Kuriyan
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

7.  The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals.

Authors:  S Gupta; H Yan; L H Wong; S Ralph; J Krolewski; C Schindler
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

8.  Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.

Authors:  Y J Zhou; E P Hanson; Y Q Chen; K Magnuson; M Chen; P G Swann; R L Wange; P S Changelian; J J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

9.  Interaction between Btk TH and SH3 domain.

Authors:  Michael P Okoh; Mauno Vihinen
Journal:  Biopolymers       Date:  2002-04-15       Impact factor: 2.505

Review 10.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

View more
  66 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

2.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

3.  Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Authors:  Geoff M Gordon; Que T Lambert; Kenyon G Daniel; Gary W Reuther
Journal:  Biochem J       Date:  2010-12-01       Impact factor: 3.857

4.  Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

Authors:  Xiaoshan Min; Daniela Ungureanu; Sarah Maxwell; Henrik Hammarén; Steve Thibault; Ellin-Kristina Hillert; Merrill Ayres; Brad Greenfield; John Eksterowicz; Chris Gabel; Nigel Walker; Olli Silvennoinen; Zhulun Wang
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

Review 5.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 6.  Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Authors:  Jacqueline Sayyah; Peter P Sayeski
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

Review 7.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

8.  Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.

Authors:  Zhe Li; Shu Xing; Shaofeng Wang; Wanting Tina Ho; Zhizhuang Joe Zhao
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

9.  The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Authors:  Zbigniew Rudzki; Tomasz Sacha; Anastazja Stój; Sylwia Czekalska; Małgorzata Wójcik; Aleksander B Skotnicki; Barbara Grabowska; Andrzej Zduńczyk; Krzysztof Okoń; Jerzy Stachura
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

10.  Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.

Authors:  John S Tokarski; Adriana Zupa-Fernandez; Jeffrey A Tredup; Kristen Pike; ChiehYing Chang; Dianlin Xie; Lihong Cheng; Donna Pedicord; Jodi Muckelbauer; Stephen R Johnson; Sophie Wu; Suzanne C Edavettal; Yang Hong; Mark R Witmer; Lisa L Elkin; Yuval Blat; William J Pitts; David S Weinstein; James R Burke
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.